Quasi-perfusion Studies for Intensified Lentiviral Vector Production Using a Continuous Stable Producer Cell Line

Overview

Journal Mol Ther Methods Clin Dev

Publisher Cell Press

Date 2024 Jun 3

PMID 38827249

Authors

Dale J Stibbs

Pedro Silva Couto

Yasuhiro Takeuchi

Qasim A Rafiq

Nigel B Jackson

Andrea C M E Rayat

Affiliations

Soon will be listed here.

Abstract

Quasi-perfusion culture was employed to intensify lentiviral vector (LV) manufacturing using a continuous stable producer cell line in an 8-day process. Initial studies aimed to identify a scalable seeding density, with 3, 4, and 5 × 10 cells cm providing similar specific productivities of infectious LV. Seeding at 3 × 10 cells cm was selected, and the quasi-perfusion was modulated to minimize inhibitory metabolite accumulation and vector exposure at 37°C. Similar specific productivities of infectious LV and physical LV were achieved at 1, 2, and 3 vessel volumes per day (VVD), with 1 VVD selected to minimize downstream processing volumes. The optimized process was scaled 50-fold to 1,264 cm flasks, achieving similar LV titers. However, scaling up beyond this to a 6,320 cm multilayer flask reduced titers, possibly from suboptimal gas exchange. Across three independent processes in 25 cm to 6,320 cm flasks, reproducibility was high with a coefficient of variation of 7.7% ± 2.9% and 11.9% ± 3.0% for infectious and physical LV titers, respectively. The optimized flask process was successfully transferred to the iCELLis Nano (Cytiva) fixed-bed bioreactor, with quasi-perfusion at 1 VVD yielding 1.62 × 10 TU.

References

Couto P, Stibbs D, Rotondi M, Takeuchi Y, Rafiq Q . Scalable manufacturing of gene-modified human mesenchymal stromal cells with microcarriers in spinner flasks. Appl Microbiol Biotechnol. 2023; 107(18):5669-5685. PMC: 10439856. DOI: 10.1007/s00253-023-12634-w. View

TRITSCH G, Moore G . Spontaneous decomposition of glutamine in cell culture media. Exp Cell Res. 1962; 28:360-4. DOI: 10.1016/0014-4827(62)90290-2. View

Merten O, Hebben M, Bovolenta C . Production of lentiviral vectors. Mol Ther Methods Clin Dev. 2016; 3:16017. PMC: 4830361. DOI: 10.1038/mtm.2016.17. View

Stibbs D, Couto P, Takeuchi Y, Rafiq Q, Jackson N, Rayat A . Continuous manufacturing of lentiviral vectors using a stable producer cell line in a fixed-bed bioreactor. Mol Ther Methods Clin Dev. 2024; 32(1):101209. PMC: 10907162. DOI: 10.1016/j.omtm.2024.101209. View

Milani M, Annoni A, Bartolaccini S, Biffi M, Russo F, Di Tomaso T . Genome editing for scalable production of alloantigen-free lentiviral vectors for gene therapy. EMBO Mol Med. 2017; 9(11):1558-1573. PMC: 5666310. DOI: 10.15252/emmm.201708148. View

Sheu J, Beltzer J, Fury B, Wilczek K, Tobin S, Falconer D . Large-scale production of lentiviral vector in a closed system hollow fiber bioreactor. Mol Ther Methods Clin Dev. 2015; 2:15020. PMC: 4470365. DOI: 10.1038/mtm.2015.20. View

Mitta B, Rimann M, Fussenegger M . Detailed design and comparative analysis of protocols for optimized production of high-performance HIV-1-derived lentiviral particles. Metab Eng. 2005; 7(5-6):426-36. DOI: 10.1016/j.ymben.2005.06.006. View

Perry C, Mujahid N, Takeuchi Y, Rayat A . Insights into product and process related challenges of lentiviral vector bioprocessing. Biotechnol Bioeng. 2023; 121(8):2466-2481. DOI: 10.1002/bit.28498. View

de Ravin S, Wu X, Moir S, Anaya-OBrien S, Kwatemaa N, Littel P . Lentiviral hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiency. Sci Transl Med. 2016; 8(335):335ra57. PMC: 5557273. DOI: 10.1126/scitranslmed.aad8856. View

10.

Lesch H, Heikkila K, Lipponen E, Valonen P, Muller A, Rasanen E . Process Development of Adenoviral Vector Production in Fixed Bed Bioreactor: From Bench to Commercial Scale. Hum Gene Ther. 2015; 26(8):560-71. DOI: 10.1089/hum.2015.081. View

11.

Fiol C, Collignon M, Welsh J, Rafiq Q . Optimizing and developing a scalable, chemically defined, animal component-free lentiviral vector production process in a fixed-bed bioreactor. Mol Ther Methods Clin Dev. 2023; 30:221-234. PMC: 10388200. DOI: 10.1016/j.omtm.2023.06.011. View

12.

Cockrell A, Ma H, Fu K, McCown T, Kafri T . A trans-lentiviral packaging cell line for high-titer conditional self-inactivating HIV-1 vectors. Mol Ther. 2006; 14(2):276-84. DOI: 10.1016/j.ymthe.2005.12.015. View

13.

Valkama A, Oruetxebarria I, Lipponen E, Leinonen H, Kayhty P, Hynynen H . Development of Large-Scale Downstream Processing for Lentiviral Vectors. Mol Ther Methods Clin Dev. 2020; 17:717-730. PMC: 7177191. DOI: 10.1016/j.omtm.2020.03.025. View

14.

Valkama A, Leinonen H, Lipponen E, Turkki V, Malinen J, Heikura T . Optimization of lentiviral vector production for scale-up in fixed-bed bioreactor. Gene Ther. 2018; 25(1):39-46. PMC: 5817386. DOI: 10.1038/gt.2017.91. View

15.

FARSON D, Witt R, McGuinness R, Dull T, Kelly M, Song J . A new-generation stable inducible packaging cell line for lentiviral vectors. Hum Gene Ther. 2001; 12(8):981-97. DOI: 10.1089/104303401750195935. View

16.

McCarron A, Donnelley M, McIntyre C, Parsons D . Transient Lentiviral Vector Production Using a Packed-Bed Bioreactor System. Hum Gene Ther Methods. 2019; 30(3):93-101. DOI: 10.1089/hgtb.2019.038. View

17.

Segura M, Kamen A, Trudel P, Garnier A . A novel purification strategy for retrovirus gene therapy vectors using heparin affinity chromatography. Biotechnol Bioeng. 2005; 90(4):391-404. DOI: 10.1002/bit.20301. View

18.

Lesch H, Valonen P, Karhinen M . Evaluation of the Single-Use Fixed-Bed Bioreactors in Scalable Virus Production. Biotechnol J. 2020; 16(1):e2000020. DOI: 10.1002/biot.202000020. View

19.

Higashikawa F, Chang L . Kinetic analyses of stability of simple and complex retroviral vectors. Virology. 2001; 280(1):124-31. DOI: 10.1006/viro.2000.0743. View

20.

Holic N, Seye A, Majdoul S, Martin S, Merten O, Galy A . Influence of mildly acidic pH conditions on the production of lentiviral and retroviral vectors. Hum Gene Ther Clin Dev. 2014; 25(3):178-85. DOI: 10.1089/humc.2014.027. View